CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech which has been effective hard but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.
In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.
CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.
While CYDY is actually dawdling, market opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV are actually closing.
I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the past few shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set out what follows prediction:
Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire interview that I came away with a bad impression of the company.
Irony of irony, my poor impression of the business enterprise has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.
What manner of stock is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; permit me to explain.
CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the therapy and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the technology as well as linked intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) along with the first new drug application endorsement ($five million), as well as royalty payments of five % of net sales upon commercialization.
Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.
As opposed to having a pipeline with numerous indications and numerous therapies, it has this single remedy as well as a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.
Its opening banner on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications and multiple presentations.
Could all this be smoke and mirrors? That’s a question I’ve been asking myself with the very start of the interest of mine in this particular business. Judging by the multiples of thousands of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.
CytoDyn is a classic battleground, or maybe some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
